Literature DB >> 11698122

Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia.

H Kook1, W Zeng, C Guibin, M Kirby, N S Young, J P Maciejewski.   

Abstract

OBJECTIVE: We hypothesized that an active autoimmune process in aplastic anemia (AA) corresponds to the expansion of cytotoxic lymphocytes (CTLs) displaying mature effector phenotype. We determined whether the numbers of effector CTLs in blood of patients with bone marrow failure syndromes are elevated and correlate with the disease activity and responsiveness to immunosuppression. PATIENTS AND METHODS: We analyzed samples from patients with AA, myelodysplastic syndrome (MDS), polytransfused patients with nonimmune-mediated hematologic disease, and normal controls for the presence of effector T lymphocytes using four-color flow cytometry. Expression of CD57 and loss of CD28 on CD8+CD3+ CTL were used as markers for the terminal effector phenotype. In addition, intracellular staining for perforin and granzyme B was preformed. The numbers of effector CTL did not differ between healthy individuals and hematologic controls and the two groups were pooled.
RESULTS: The percentages of CD8+CD28- and CD8+CD28-CD57+ cells were significantly higher in AA and MDS patients than in controls. There was a trend toward a gradual decrease in the effector CTLs from the high values observed in untreated new patients and patients who did not respond to immunosuppression, intermediate levels for partial responders and complete responders, to the lowest levels seen in controls. However, severity of pancytopenia did not correlate with the size of the effector cell population. In contrast to CD57+ CTLs, expression of perforin or granzyme B in the cytotoxic effector cells did not differ in AA patients from those of controls.
CONCLUSIONS: Our results indicate that phenotypically defined effector CTLs are increased in AA and MDS and the effector phenotype may be useful to isolate and characterize antigen-specific T cells in AA in order to delineate the possible inciting or driving agents in AA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698122     DOI: 10.1016/s0301-472x(01)00736-6

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  29 in total

Review 1.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 2.  Immune pathophysiology of aplastic anemia.

Authors:  Shinji Nakao; Xingmin Feng; Chiharu Sugimori
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

4.  CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia.

Authors:  Christina Arieta Kuksin; Gabriela Gonzalez-Perez; Lisa M Minter
Journal:  Blood       Date:  2015-02-03       Impact factor: 22.113

Review 5.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

6.  Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.

Authors:  Tapan M Kadia; Gautam Borthakur; Guillermo Garcia-Manero; Stefan Faderl; Elias Jabbour; Zeev Estrov; Sergerrne York; Xuelin Huang; Sherry Pierce; Mark Brandt; Charles Koller; Hagop M Kantarjian; Farhad Ravandi
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

Review 7.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

8.  PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model.

Authors:  Maile K Hollinger; Valentina Giudice; Nicole A Cummings; Guillermo Rivell; Hansheng Zhang; Sachiko Kajigaya; Keyvan Keyvanfar; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2018-03-07       Impact factor: 3.084

Review 9.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

10.  CD8+ T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure.

Authors:  David M Gravano; Mufadhal Al-Kuhlani; Dan Davini; P Dominick Sanders; Jennifer O Manilay; Katrina K Hoyer
Journal:  J Autoimmun       Date:  2016-07-21       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.